Trials / Completed
CompletedNCT00572364
Open Label, Dose Escalation Phase I Study of AZD2281
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-03-01
- Completion
- 2009-06-01
- First posted
- 2007-12-13
- Last updated
- 2009-08-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00572364. Inclusion in this directory is not an endorsement.